Literature DB >> 28605417

Reply to Naktin.

John A Branda1, Allen C Steere2.   

Abstract

Mesh：

Year:  2017        PMID： 28605417      PMCID： PMC5848297          DOI： 10.1093/cid/cix545

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN： 1058-4838            Impact factor:   9.079


× No keyword cloud information.
  8 in total

1.  The presenting manifestations of Lyme disease and the outcomes of treatment.

Authors:  Allen C Steere; Vijay K Sikand
Journal:  N Engl J Med       Date:  2003-06-12       Impact factor: 91.245

2.  Evaluation of Modified 2-Tiered Serodiagnostic Testing Algorithms for Early Lyme Disease.

Authors:  John A Branda; Klemen Strle; Lise E Nigrovic; Paul M Lantos; Timothy J Lepore; Nitin S Damle; Mary Jane Ferraro; Allen C Steere
Journal:  Clin Infect Dis       Date:  2017-04-15       Impact factor: 9.079

3.  Diagnostic Utility of Erythema Migrans.

Authors:  Jaan Peter Naktin
Journal:  Clin Infect Dis       Date:  2017-11-29       Impact factor: 9.079

4.  Clinical characteristics and treatment outcome of early Lyme disease in patients with microbiologically confirmed erythema migrans.

Authors:  Robert P Smith; Robert T Schoen; Daniel W Rahn; Vijay K Sikand; John Nowakowski; Dennis L Parenti; Mary S Holman; David H Persing; Allen C Steere
Journal:  Ann Intern Med       Date:  2002-03-19       Impact factor: 25.391

5.  Prospective clinical evaluation of patients from Missouri and New York with erythema migrans-like skin lesions.

Authors:  Gary P Wormser; Edwin Masters; John Nowakowski; Donna McKenna; Diane Holmgren; Katherine Ma; Lauren Ihde; L Frank Cavaliere; Robert B Nadelman
Journal:  Clin Infect Dis       Date:  2005-08-31       Impact factor: 9.079

6.  The clinical assessment, treatment, and prevention of lyme disease, human granulocytic anaplasmosis, and babesiosis: clinical practice guidelines by the Infectious Diseases Society of America.

Authors:  Gary P Wormser; Raymond J Dattwyler; Eugene D Shapiro; John J Halperin; Allen C Steere; Mark S Klempner; Peter J Krause; Johan S Bakken; Franc Strle; Gerold Stanek; Linda Bockenstedt; Durland Fish; J Stephen Dumler; Robert B Nadelman
Journal:  Clin Infect Dis       Date:  2006-10-02       Impact factor: 9.079

7.  Lyme disease testing by large commercial laboratories in the United States.

Authors:  Alison F Hinckley; Neeta P Connally; James I Meek; Barbara J Johnson; Melissa M Kemperman; Katherine A Feldman; Jennifer L White; Paul S Mead
Journal:  Clin Infect Dis       Date:  2014-05-30       Impact factor: 9.079

8.  Vaccination against Lyme disease with recombinant Borrelia burgdorferi outer-surface lipoprotein A with adjuvant. Lyme Disease Vaccine Study Group.

Authors:  A C Steere; V K Sikand; F Meurice; D L Parenti; E Fikrig; R T Schoen; J Nowakowski; C H Schmid; S Laukamp; C Buscarino; D S Krause
Journal:  N Engl J Med       Date:  1998-07-23       Impact factor: 91.245
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.